Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of disitamab vedotin in HER2-expressing advanced or metastatic castration-resistant prostate cancer
CTR20240139Phase 2Active
- Sponsor
- RemeGen
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in prostate cancer (PCa), sponsored by RemeGen. Started Apr 2024; status: active.
02
Drugs
disitamab vedotin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20240139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240139.